Clinical trial
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or…
NCT00004066 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004066 |
|---|---|
| Title | Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma |
| Official title | A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Sarcoma, Small Intestine Cancer |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, docetaxel, gemcitabine hydrochloride |
| Enrollment | 82 |
| Start date | Jun 1, 1999 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: